ClinCalc Pro
Menu
Progestogen Pregnancy: Used in pregnancy — not associated with fetal abnormalities in doses used for luteal support

Progesterone (Vaginal)

Brand names: Cyclogest (pessary), Utrogestan (capsule), Lubion (injection)

Adult dose

Dose: Luteal phase support (IVF): 400–600 mg intravaginally daily in divided doses. Threatened miscarriage/recurrent miscarriage: 400 mg BD vaginally.
Route: Vaginal pessary or capsule
Frequency: BD–TDS
Max: 1200 mg/day vaginally
PROMISE trial: vaginal progesterone did NOT reduce miscarriage in unselected women but showed benefit in women with previous miscarriage + subchorionic haematoma. PRISM trial (NEJM 2019): progesterone in early pregnancy vaginal bleeding — benefit in women with recurrent miscarriage.

Paediatric dose

Route: N/A
Frequency: N/A
Max: Not applicable
Not applicable in paediatric patients

Dose adjustments

Renal

No dose adjustment required

Hepatic

Avoid in hepatic impairment — hepatically metabolised

Clinical pearls

  • PRISM trial: 400 mg BD vaginal progesterone in women with first trimester bleeding + previous miscarriage showed statistically significant increase in live birth rates
  • IVF luteal support: commenced day of egg collection/embryo transfer, continued until 8–12 weeks gestation
  • Utrogestan capsules used vaginally (off-label route but clinically standard)
  • Do not use for routine threatened miscarriage in women with no previous loss — current NHS England guidance

Contraindications

  • Unexplained vaginal bleeding (until ectopic and miscarriage excluded)
  • Hormone-sensitive cancer
  • Severe hepatic impairment
  • Thromboembolic disease

Side effects

  • Local vaginal irritation or discharge
  • Somnolence (if oral route used)
  • Nausea
  • Bloating
  • Breast tenderness

Interactions

  • Rifampicin/antiepileptics — reduced progesterone levels (enzyme inducers)

Monitoring

  • Serum progesterone (IVF cycles)
  • Symptoms of threatened miscarriage
  • Vaginal discharge/local irritation

Reference: BNFc; BNF; PRISM Trial (Coomarasamy et al, NEJM 2019); ESHRE ART Guidelines. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.